Answers are grounded in this paper and cite their sources.
The efficacy of once-weekly somatrogon was noninferior to once-daily somatropin, with similar safety and tolerability profiles. (ClinicalTrials.gov no. NCT02968004).
No takes yet. Share an insight, caveat, or question.
Deal et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: